pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 48 | Non-oncology: 27 Oncology: 21 |
| Under Consideration for Negotiation | 19 | Non-oncology: 9 Oncology: 10 |
| Completed Negotiations | 902 | With Letter of Intent: 778 Without agreement: 124 |
| Negotiations That Were Not Pursued | 113 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Okedi | Bausch Health, Canada Inc. | Schizophrenia in Adults | |
| Hepcludex | Gilead Sciences Canada Inc. | Chronic hepatitis delta virus (HDV) infection | |
| Enhertu | AstraZeneca Canada Inc. | For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the meta | |
| Nemluvio | Galderma Canada Inc. | Prurigo nodularis | |
| Nemluvio | Galderma Canada Inc. | For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy. | |
| Andembry | CSL Behring Canada Inc. | Hereditary Angioedema | |
| Anzupgo | LEO Pharma Inc. | Chronic hand eczema | |
| Zepzelca (active pTAP negotiation) | Jazz Pharmaceuticals Canada Inc. | For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy. | |
| Opzelura | Incyte Biosciences Canada Corporation | Atopic dermatitis | |
| Sarclisa | Sanofi Genzyme Canada | In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). | |
| Epuris | Cipher | Acne Vulgaris | |
| Itovebi | Hoffmann-La Roche Ltd. | In combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor-positive (HR+) (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or meta |